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ABSTRACT: Under the evolutionary pressure exerted by the emergence
of adaptive immunity and its inherent risk of horror autotoxicus, the thy-
mus appeared some 500 million years ago as a novel lymphoid structure
able to prevent autoimmunity and to orchestrate self-tolerance as a cor-
nerstone in the physiology of the immune system. Also, the thymus plays
a prominent role in T cell education to neuroendocrine principles. Some
self-antigens (oxytocin, neurotensin, insulin-like growth factor 2 [IGF-2])
have been selected to be predominantly expressed in thymic epithelium
and to be presented to thymus T cells for educating them to tolerate other
antigens related to them. In the insulin family, IGF2 is dominantly tran-
scribed in cortical (c) and medullary (m) thymic epithelial cells (TECs),
whereas the insulin gene (INS) is expressed at low level by only a few
subsets of mTECs. Intrathymic transcription of both IGF2 and INS is
under the control of the autoimmune regulator (Aire) gene. The highest
concentrations of IGF-2 in the thymus explain why this peptide is much
more tolerated than insulin, and why tolerance to IGF-2 is so difficult
to break by active immunization. The high level of tolerance to IGF-2 is
correlated to the development of a tolerogenic/regulatory profile when
the sequence B11-25 of IGF-2 (homologous to the autoantigen insulin
B9-23) is presented to DQ8+ type 1 diabetic patients. Since subcuta-
neous and oral insulin does not exert any tolerogenic properties, IGF-2
and other thymus self-antigens related to type 1 diabetes (T1D) should
be preferred to insulin for the design of novel specific antigen-based pre-
ventive approaches against T1D.
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INTRODUCTION
Some 500 million years ago, although some rudiment of immune diversity
already existed in jawless fishes (e.g., lamprey),1 novel adaptive immunity
emerged in cartilaginous fishes (e.g., shark and ray). Specialized recombi-
nation machinery in somatic lymphoid cells is the fundamental property of
adaptive immunity and is responsible for the random generation of a huge
diversity of immune receptors (BCRs and TCRs) able to recognize non-self
antigens. The emergence of this novel form of immune defense exerted such a
potent pressure that novel structures and mechanisms appeared along the paths
of lymphocyte traffic to impose immunological self-tolerance, that is, the in-
ability of the immune system to attack the host organism. Together with the
generation of diversity and memory, self-tolerance is a cornerstone in physiol-
ogy and homeostasis of the immune system. The progressive rise in the level
of immune diversity and complexity also explains why failures of immuno-
logical self-tolerance (such as organ-specific autoimmune diseases) are more
and more frequently detected in parallel with evolution, the maximum being
observed in the human species. The first thymus also appeared in cartilaginous
fishes concomitant with the emergence of adaptive immunity. Though some
forms of tolerance induction already take place in primary hematopoietic sites
(fetal liver and bone marrow), antigen-dependent B cell tolerance is predomi-
nantly due to an absence of T cell help. So, among all lymphoid structures, the
thymus is the only organ specialized in the establishment of immunological
self-tolerance.
The thymus crucially stands at the crossroads between the immune and neu-
roendocrine systems.2 Within this organ responsible for thymopoiesis (T cell
generation), the neuroendocrine system regulates the process of T cell differ-
entiation from the very early stages. In addition, T lymphocytes undergo in
the thymus a complex educative process that establishes central T cell self-
tolerance of neuroendocrine principles. The thymus is a very unique place
wherein these is a permanent confrontation between ancient, almost constant,
neuroendocrine principles and a recent system equipped with a sophisticated
machinery promoting stochastic generation of response diversity. Contrary to
a previous assumption, the thymus functions throughout life and plays a fun-
damental role in the recovery of a competent T cell repertoire after intensive
chemotherapy or during highly active antiretroviral therapy.3,4 Finally, the thy-
mus is an important site for the generation of self-antigen specific regulatory
T cells (TR) that suppress in the periphery the activation of self-reactive T cells
that have escaped the thymus central censorship.5,6
DEVELOPMENTAL BIOLOGY OF THYMIC EPITHELIUM
Epithelial cells of the thymic cortex (cTEC, including thymic “nurse” cells
[TNC]) and medulla (mTEC) originate from a common progenitor derived
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around embryonic day 11 (E11) from the endoderm of the third pharyngeal
pouch.7,8 Using lineage tracing analysis in whole embryo culture, no evidence
was found for a contribution from the ectoderm of the third pharyngeal cleft.
Further development of this primitive epithelial rudiment depends upon a con-
tribution from the cephalic neural crest. Some human diseases (and animal
models) include a defective thymus development, leading to primary immune
deficiencies. DiGeorge’s syndrome associates congenital absence (or hypopla-
sia) of thymus and parathyroids with defects in the heart and truncal vessels.
This syndrome partly results from a migration failure of the cephalic neu-
ral crest. Mice in whom the homeobox A3 gene (Hoxa3) has been disrupted
present thymic aplasia, parathyroid hypoplasia, and frequent defects in heart
and great vessels.9 Wild animals with immune deficiencies most closely re-
lated to DiGeorge’s syndrome are “nude” mice with hairlessness and lack of
thymic development resulting from defects in TECs. The “nude” phenotype
is caused by mutations in the nude gene on murine chromosome 11 that en-
codes the transcription factor winged-helix nude (whn) or forkhead box N1
(Foxn1).10 Wnt glycoproteins and dependent signaling were shown to regu-
late Foxn1 expression in TECs.11 In the absence of functional Foxn1, TECs
are arrested at an immature progenitor stage (with expression of MTS20+
and MTS24+ determinants) and do not differentiate into epithelial subre-
gions.12 Different studies indicate that a common progenitor of TECs might
exist, with a marker phenotype of MTS20+ MTS24+ cytokeratin 5 (K5+)
and K8+. Once further identified, such TEC progenitor lines could be used
for restoring thymus function in DiGeorge’s syndrome or in immunosenes-
cence, as well as for improving the final outcome after bone marrow and organ
transplantations.
Five other transcription factors, paired box gene 1 (Pax1), and 9 (Pax9),
eyes absent 1 homologue (Eya1), and sine oculis–related homeobox 1 ho-
mologue (Six1), also contribute to the ontogeny of thymic epithelium. In
mice, these genes are coexpressed only in the pharyngeal endoderm and in
the cephalic neural crest–derived mesenchyme (with the exception of Pax1
and Pax9).7 Important developmental signaling pathways (fibroblast growth
factors [FGFs], bone morphogenetic proteins [BMP], and sonic-hedgehog ho-
mologue [Shh]) are also implicated in cell–cell interactions between thymic
epithelium and mesenchymal cells, as well as the surrounding neural crest–
derived mesenchyme (reviewed in Ref. 13 ).
From fetal liver and then bone marrow, T cell progenitors migrate into the
thymus through the boundary between cortex and medulla, undergo around
20 division cycles in the outer cortex, and then differentiate after presentation
of peptides by major histocompatibility complex (MHC) proteins expressed
by thymic antigen-presenting cells (APCs), that is, cTECs, mTECs, dendritic
cells (DCs), macrophages, and rare thymus B cells. The random rearrangement
of related  then  loci generates an enormous diversity of TCRs, a great
number of which are able to bind peptide/MHC ligands with high affinity and
to be negatively selected. Negative selection can occur in both the cortex and
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the medulla,14 though mTECs display the most complete APC competence.
At the end of the differentiation process in the thymus, only ± 5% of naı¨ve
thymus T cells (thymocytes) will leave the organ in a state of self-tolerance
and competence against infectious non-self antigens.
THE NEUROENDOCRINE SELF
From the investigation of the intrathymic expression of neuroendocrine-
related self-peptide precursor genes, a series of specificities could be listed
to define the nature of “neuroendocrine self.” 15 (1) Neuroendocrine self-
antigens usually correspond to peptide sequences that have been highly con-
served throughout the evolution of one given family. (2) A hierarchy charac-
terizes their expression pattern. In the neurohypophysial family, oxytocin (OT)
is the dominant peptide synthesized by TEC/TNCs from different species. The
binding of OT to OT receptor (OTR) expressed by pre-T cells induces a very
rapid phosphorylation of focal adhesion–related kinases.16–18 This event could
play a major role in the promotion of “immunological synapses” between im-
mature T lymphocytes and thymus APCs. Concerning the tachykinin family,
neurokinin A (NKA)—but not substance P (SP)—is the peptide generated
from the processing by TECs of the preprotachykinin A (PPT-A) gene prod-
uct.19 With regard to the insulin gene family, all members are expressed in
the thymus network according to a precise hierarchy and topography: IGF2
(cTEC/TNC and mTEC) > IGF1 (thymic macrophages) > INS (mTEC).20–23
This hierarchical pattern is significant since the tolerogenic response primarily
concerns the dominant epitopes of a protein family. Contrary to (pro)insulin,
the blockade of thymic IGF-mediated signaling, at the level of IGF ligands (in
particular IGF-2) or IGF receptors, interferes with the early stages of T cell
differentiation in fetal thymic organ cultures (FTOCs).24 (3) Neuroendocrine
precursors are not processed according to the classic model of neurosecretion,
but they undergo antigenic processing for presentation by—or in association
with—MHC proteins. (4) This processing differs between thymic APCs and
dedicated peripheral APCs. At least for some neuroendocrine self-antigens (OT
and neurotensin), such differences imply that presentation by thymic APCs is
not tightly restricted by MHC alleles as much as presentation of infectious non
self antigens and autoantigens by peripheral dedicated APCs (macrophages,
DCs, and B cells).
During ontogeny of Balb/c mice, OT transcripts are detected on E13 both in
thymus and brain, whereas vasopressin (VP) gene transcription starts on E14
in the brain and is clearly detected in the thymus only on E15.25 The earlier
OT expression in the thymus strongly supports the role of thymic OT in the
induction of central T cell tolerance of the neurohypophysial peptides before
their appearance in the hypothalamic magnocellular neurons. The expression
of the neurohypophysial receptor genes (OTR, V1, V2, and V3) was investigated
on murine CD4− CD8− T cell lines, as well as on murine T cell subsets. OTR
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transcripts are detected in CD4−CD8−, CD4+ CD8+, and CD8+ cells, while a
very faint V3 expression is restricted to CD4+ CD8+ and CD8+ cells. V1 and
V2 expression could not be detected on any T cell subset. In FTOCs, a specific
OTR antagonist increases late T cell apoptosis, confirming the involvement of
OT/OTR signaling in T cell proliferation/survival.25,26
REGULATION OF SELF-EXPRESSION
The progressive accumulation of evidence that genes/proteins considered to
be expressed only in the brain, in the neuroendocrine system, and in peripheral
organs are also synthesized in the thymus finally brought into question the com-
mon view of the establishment of immunological self-tolerance and the devel-
opment of organ-specific autoimmunity (completely reviewed in Ref. 27). In
1993, the term “promiscuous” was introduced to specify this unique promoter
use by TECs compared to other somatic cells.28 Another advance in the current
reappraisal of the crucial role played by the thymus in preventing autoimmunity
came from the identification of the gene of which mutations are responsible
for the polyendocrine autoimmune disease, autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) or autoimmune polyglandular
syndrome type 1 (APS-1).29,30 The gene Aire (autoimmune regulator) encodes
a protein with structural and functional features suggesting a transcription
factor. The generation of Aire−/− mice revealed that Aire primarily functions
within TECs where its expression is maximal and where it controls transcrip-
tion of genes encoding neuroendocrine self-antigens (including Ot, Igf2, Ins2,
and Npy), as well as a series—but not all—tissue-restricted antigens.31 Al-
though Aire controls the transcription of these two neuroendocrine-related
genes, Ins2 expression is restricted to mTEC, while Igf2 transcripts are detected
in cTEC/TNCs, as well as in mTECs. The existence of epigenetic mechanisms
in the Aire control of self-expression is also strongly supported by the dis-
covery that the set of promiscuous transcripts expressed by human mTECs
includes several groups of chromosomally clustered genes.32 Such epigenetic
regulation is further suggested by loss of imprinting and overexpression of
IGF2 in human mTECs.33 Nevertheless, it remains unclear why TECs are the
only somatic cells (with the exception of multipotent stem cells) to transcribe
such a diversity of neuroendocrine and tissue-restricted antigens, and why this
diversity seems to be correlated with the stage of TEC differentiation.
Aire promotes negative selection of self-reactive thymus T cells and, perhaps
more importantly, improves the overall efficiency of antigen presentation by
mTECs.34,35 As previously mentioned, a difference between the central and
peripheral mechanisms was again evidenced at this level since antigen pre-
sentation by DCs in the periphery is more efficient in the absence of Aire.36
On the other hand, no any significant defect of the TR lineage was observed
in Aire-deficient mice. Very interestingly, thymic Aire expression decreases
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and autoimmunity develops in lymphotoxin (LT)  or  receptor–deficient
mice.37 Although it is still not clear whether the LT receptor directly controls
Aire expression or indirectly via regulation of mTEC development, this study
illustrates the importance of lymphoepithelial crosstalk in thymus physiology.
Human thymic stromal lymphopoietin (TSLP) has also been reported to in-
duce AIRE expression in human DC.38 Although helix-loop-helix transcription
factors of the forkhead family (Foxn1, Foxp3, Foxo, and Foxj1) are major mod-
ulators of the immune development and responses, Aire seems to be until now
the unique molecular determinant involved in the control of self-expression
inside the thymus.
Altogether, those studies contributed to reevaluate the physiological impor-
tance of thymus-dependent central tolerance and “recessive” clonal deletion—
as opposed to the “dominant” tolerance by TR generation—in the prevention
of autoimmunity and “horror autotoxicus” of the organism, so to speak in a
conceptual view like that proposed by Ehrlich in 1901.39 Self-tolerance home-
ostasis and prevention of autoimmunity by central and peripheral tolerogenic
mechanisms acting synergically have, however, to be considered together as
evidenced by the severe and multiple autoimmune organ deficiencies as ob-
served in Foxp3- and Foxj1-deficient mice.40,41
PRESENTATION OF NEUROENDOCRINE SELF-ANTIGENS
While a vast repertoire of neuroendocrine-related and tissue-restricted self-
antigens is expressed by TECs, the coupling of their thymic transcription to the
MHC presentation of derived epitopes has not been extensively investigated.
This point is, however, fundamental since some authors recently reported that
the promiscuous gene expression of an autoantigen gene (H/Ka subunit of the
gastric membrane protein H+/K+ ATPase) did not result in negative selection
of effector self-reactive T cells.42
Using an immunoaffinity column prepared with a mAb to the monomorphic
part of human MHC-I molecules, we identified in proteins extracted from
human TEC plasma membranes a 55-kDa protein that was labeled both by
anti-MHC-I and antineurophysin antibodies.43 This membrane protein may
represent a hybrid protein with a neurophysin domain (10 kDa) and a MHC-I
heavy chain domain (45 kDa). Formation of such a hybrid protein could reside
either at the posttranscriptional level (such as a transsplicing mechanism), or
at the posttranslational level (such as the ATP-dependent binding of ubiquitin
to proteins in proteolysis). The MHC-I domain would be implicated in the
membrane targeting of this 55-kDa protein, while neurophysin would bind OT
for presentation to thymus T cells. If this assumption were correct, this would
mean that, both in the hypothalamo-neurohypophysial axis and in the thymus,
the neurophysin part of the OT precursor fulfills the same function: binding
of OT and transport to the surface of magnocellular neurons or TEC/TNCs. If
290 ANNALS NEW YORK ACADEMY OF SCIENCES
true, this explanation would imply that the immune system has adopted during
evolution a component of the neurohypophysial peptide biosynthesis for the
development of tolerance to the self-antigen OT of this family. Interestingly,
with regard to this hypothesis, it was recently demonstrated that a component of
lipid metabolism, the binding protein apolipoprotein E, is used by the immune
system for binding lipid antigens and delivering them into DC endosomal
compartments containing CD1.44 Further studies are needed to verify whether
IGF-binding proteins could also be involved in the intrathymic presentation of
IGF-2 to thymus T cells. This hypothesis is nevertheless plausible since several
genes encoding these important components of the IGF system are transcribed
in the thymus network.22
Cultured human TECs contain ± 5 ng neurotensin (NT) per 106 cells, of
which 5% are associated with plasma cell membranes. HPLC analysis of im-
munoreactive (ir)-NT present in human TECs revealed a major peak of ir-NT
corresponding to intact NT1-13. Ir-NT was not detected in the supernatant
of human TEC primary cultures. Using an immunoaffinity column with an
anti-MHC-I mAb, NT-related peptides were retained on the column and were
eluted at basic pH just as antigens bound to MHC-I proteins.45 The C-terminal
sequence of NT includes tyrosine, leucine, and isoleucine, all residues that can
be used for anchorage to most of the MHC-I alleles. Thus, NT and NT-derived
C-terminal fragments could behave as natural ligands for a majority (if not all)
of MHC-I alleles. This hypothesis stands in agreement with the high degree
of conservation of NT-related C-terminal region throughout evolution.
DEFECTIVE CENTRAL TOLERANCE AS A PRIMARY EVENT
FOR THE DEVELOPMENT OF
AUTOIMMUNE ENDOCRINOPATHIES
In 1992, a defect in the process of T cell education to recognize and to tol-
erate the neurohypophysial self-Ag OT was hypothesized to play a pivotal role
in the development of hypothalamus-specific autoimmunity and “idiopathic”
diabetes insipidus.46 As already hypothesized by Burnet in 1973, the pathogen-
esis of autoimmune diseases could result from the appearance of “forbidden”
self-reactive effector T cell clones in the peripheral repertoire.47 Since the thy-
mus is the primary site for induction of self-tolerance, thorough investigation
of a defective thymic censorship should provide the scientific community with
important keys to understand the mechanisms underlying the development of
autoimmunity. A number of abnormalities of thymic morphology and cytoar-
chitecture have been described for several autoimmune disorders. Apoptosis
of self-reactive T cells is also defective in the thymus of NOD mice.48 The
expression of Aire is maximal in murine mTECs, but is absent in TECs of
diabetic NOD mice.49 The expression of insulin-related genes was analyzed in
thymus, liver, and brain of a common animal model of type 1 diabetes (T1D),
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the biobreeding (BB) rat. A thymus-specific defect of Igf2 expression was
evidenced in more than 80% of diabetes-prone BB rats (BBDP).50 This defect
could explain both lymphopenia, including a lack of antigen-specific TR cells
that control autoimmune diabetes, as well as absence of central self-tolerance
of insulin family in BBDP rats. Further experimental data arguing for a role
the promotion of -cell self-tolerance by thymic insulin-related peptides came
from other recent experiments showing that susceptibility to diabetes was cor-
related with the intrathymic levels of Ins2 expression.51,52 As a consequence
of the defective thymic censorship, self-reactive T cells bearing TCRs oriented
against dominant epitopes of insulin-related peptides could continuously mi-
grate from the thymus and enrich the peripheral pool with self-reactive T cells
exhibiting a potential cytotoxic power against islet  cells. Under certain en-
vironmental influences, a molecular “bridge” could be installed between the
target autoantigenic epitopes, leading to activation of the self-reactive T cell
pool and subsequent -cell destruction.
T1D (juvenile or insulin-dependent diabetes) is a chronic devastating disease
resulting from an autoimmune response specifically oriented against pancre-
atic islet  cells, the only cells secreting insulin according to the endocrine
model. In accordance with the above hypothesis, INS transcripts were measured
at lower levels in the thymus of human fetuses with short class I variable num-
ber of tandem repeats (VNTR) alleles, a genetic trait of T1D.53,54 A very recent
study also provided evidence that both IDDM2 alleles and AIRE expression
could influence the level of INS expression in the human thymus.55
THEORETICAL PRINCIPLES OF “NEGATIVE
SELF-VACCINATION”
The study of neuroendocrine gene expression and precursor processing in
the thymus led to the identification of neuroendocrine self-peptides. With re-
gard to insulin-related gene expression in the thymus, IGF-2 —a prominent
fetal growth factor—was identified as the dominant self-peptide precursor of
the insulin family expressed in the thymus from different species. This ob-
servation is in close accordance with the theory of self-recognition, which,
according to F.M. Burnet, is not an inherited property but is gradually ac-
quired in the course of fetal life. Although the tolerogenic properties of neu-
roendocrine self-peptides remain to be further documented, they are strongly
suspected from what is known about the immunological tolerance of classic
hormones. The development of specific antibodies by active immunization
(i.e., experimental breakdown of self-tolerance) revealed that OT is more tol-
erated than VP, and that IGF-2 is also more tolerated than IGF-1, and much
more than insulin. Some cases of diabetes insipidus result from an autoimmune
process against VP-producing hypothalamic neurons (infundibulohypothala-
mitis).56–58 Insulin is the primary autoantigen tackled by the autoimmune
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response observed in T1D, and the intrinsic immunogenicity of insulin might
result from its very low expression in the thymus. On the contrary, autoim-
munity has never been observed against OT and IGF-2. The strong tolerance
of these peptides, resulting from the high expression of OT and IGF2 in the
thymus, may be considered as the consequence of some evolutionary pressure
to protect fundamental processes, such as species reproduction and individ-
ual ontogeny, respectively.59–61 The putative pathogenic role of “forbidden”
self-reactive T cells against IGF-2 deserves to be further analyzed through im-
munization of Igf2−/− mice.62 In this latter model, nevertheless, the absence
of IGF-2 was clearly shown to decrease immunological tolerance to insulin.
Thus, while VP and insulin behave as the immunogenic autoantigens of
their respective families, OT and IGF-2 may be viewed as the tolerogenic self-
peptide precursors of the neurohypophysial and insulin families, respectively.
In this perspective, recent experiments have shown that, compared to insulin
B9-23, the presentation of the homologous peptide sequence IGF-2 B11-25 to
PBMC purified from DQ8+ T1D adolescents elicits a tolerogenic/regulatory
profile with a higher IL-10/IFN- ratio and a lower IL-4 secretion.63 Per-
haps it is now appropriate to distinguish an autoantigen from a self-antigen,
in the sense that peripheral autoantigens possess “altered” peptide sequences
compared to homologous thymic self-antigens. Though they are highly evolu-
tionarily related, they are not identical and this biochemical difference could
drive completely opposite immune responses (i.e., immunogenic vs. tolero-
genic responses). Undoubtedly, the reevaluation of thymus-dependent central
self-tolerance will lead to the design of novel strategies to cure and prevent se-
vere autoimmune diseases (such as T1D) that constitute the heavy tribute paid
by mankind, for the diversity, complexity, and efficiency of human immune
defenses.
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